Overview

An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Status:
Active, not recruiting

Trial end date:
2021-11-18

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and efficacy of nivolumab in combination with rucaparib, docetaxel, or enzalutamide in participants with castration-resistant prostate cancer that has spread.

Phase:

Phase 2

Details

Lead Sponsor:

Bristol-Myers Squibb

Collaborators:

Astellas Pharma Inc
Clovis Oncology
Clovis Oncology, Inc.

Treatments:

Antibodies, Monoclonal
Docetaxel
Nivolumab
Prednisone
Rucaparib